




CELEBRATING VACCINES ON THE HORIZON & FAITH LEADERS AS MESSENGERS OF HOPE

▪ Francesca Merico, Faith and Community Initiative, 9 December 2020



Be strong, courageous and hopeful! Tens of thousands of scientists are working around the clock; researchers are finding creative ways to donate their time, supplies and expertise to defeat COVID-19.



The search for a COVID-19 vaccine has united the planet's scientific and medical communities in unprecedented ways. Let's unite in prayer to support their efforts!



THE ACT ACCELERATOR & COVAX

- The **Access to COVID-19 Tools (ACT) Accelerator** is a global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
- **COVAX is the vaccines pillar of the ACT Accelerator**
- COVAX is a collaborative platform, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO - with more than two-thirds of the world engaged.
- The purpose of COVAX is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.






- At an early stage of the COVID-19 pandemic, it became clear that we don't just need COVID-19 vaccines, we also need to ensure that everyone in the world has access to them. This led to the creation of COVAX.
- The COVAX Facility brings all participating countries together – regardless of their income level – for the development, procurement, introduction and distribution of COVID-19 vaccines.
- **COVAX has the world's largest and most diverse portfolio of COVID-19 vaccine candidates.**




COVAX has been created to maximise our chances of successfully developing COVID-19 vaccines and manufacture them in the quantities needed to end this crisis.





THE GOALS OF THE COVAX FACILITY

- 1. To develop a large and diverse portfolio of COVID-19 vaccine candidates
 - 2. To deliver at least 2 billion doses of approved vaccines by the end of 2021
 - 3. To guarantee access to approved vaccines for every participating economy
 - 4. To end the acute phase of the pandemic by the end of 2021
- 

Stages of vaccine development

A vaccine must go through multiple stages before being green lit for use. An initial research and development stage is followed by a series of pre-clinical and clinical trials. Typically each step can take two years or more to complete.



THE FULL LIST OF CEPI-SUPPORTED CANDIDATE VACCINES IS AS FOLLOWS:

- Inovio, United States of America (Phase I/II)
- Moderna, United States of America (Implementation)
- CureVac, Germany (Phase I)
- Institut Pasteur/Merck/Themis, France/ United States of America /Austria (Preclinical)
- AstraZeneca/University of Oxford, United Kingdom of Great Britain and Northern Ireland (Phase III)
- University of Hong Kong, China (Preclinical)
- Novavax, United States of America (Phase I/II)
- Clover Biopharmaceuticals, China (Phase I)
- University of Queensland/CSL, Australia (Phase I)
- The nine candidate vaccines that are currently being evaluated for inclusion in the COVAX Facility include two from China, two from the United States of America, one from Republic of Korea, one from the United Kingdom of Great Britain and Northern Ireland and one global, multi-manufacture partnership. Two of these are in Phase I trials, two are tech transfers and the remainder are at the discovery stage.



What COVAX offers



Doses for at least 20%
of countries'
populations



Diverse and actively
managed portfolio of
vaccines



Vaccines delivered as
soon as they are
available



End the acute phase
of the pandemic




Rebuild economies




WHY WE NEED COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.


The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US\$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.




In the time of COVID-19,
it is the spirit of global
togetherness that gives us
hope – COVID-19 will be
defeated once all people, in
all countries, are protected
– through our joint
actions - from the novel
coronavirus.




Be the voice of hope
and wisdom in these
challenging times –
Share accurate scientific
information about
COVID-19 in your faith
community.



“COVID-19 vaccines have been identified which are SAFE and EFFECTIVE. Now we can pray together that these will be available soon to those who most need them, including frontline workers and the older loved ones in our communities.”



“We also need to continue now more than ever, because of the spread of COVID-19, to ensure we continue simple steps for PREVENTION that work... Wash your hands, Watch your distance, and Wear a mask.”



*90-Year-Old Woman
First to Receive Covid-19
Vaccine in Britain*



THANK YOU



THE 80 COUNTRIES THAT HAVE SUBMITTED EXPRESSIONS OF INTEREST TO THE GAVI-COORDINATED COVAX FACILITY INCLUDE 43 THAT HAVE AGREED TO BE PUBLICLY NAMED:

- Andorra, Argentina, Armenia, Botswana, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Dominican Republic, Estonia, Finland, Greece, Iceland, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, Luxembourg, Mauritius, Mexico, Monaco, Montenegro, New Zealand, North Macedonia, Norway, Palau, Portugal, Qatar, Republic of Korea, San Marino, Saudi Arabia, Seychelles, Singapore, South Africa, Switzerland, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland and Venezuela



IN JULY THE GAVI BOARD AGREED ON THE 92 ECONOMIES THAT WILL BE SUPPORTED THE COVAX ADVANCE MARKET COMMITMENT (AMC). THE FULL LIST IS AS FOLLOWS:

- **Low income:** Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Democratic Republic of the Congo, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Democratic People's Republic of Korea, Liberia, Madagascar, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda, Sierra Leone, Somalia, South Sudan, Syrian Arab Republic, Tajikistan, Togo, Uganda, United Republic of Tanzania and Yemen.
- **Lower-middle income:** Angola, Algeria, Bangladesh, Bhutan, Bolivia, Cabo Verde, Cambodia, Cameroon, Comoros, Congo, Côte d'Ivoire, Djibouti, Egypt, El Salvador, Eswatini, Ghana, Honduras, India, Indonesia, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Lesotho, Mauritania, Micronesia, Moldova, Mongolia, Morocco, Myanmar, Nicaragua, Nigeria, Pakistan, Papua New Guinea, Philippines, São Tomé and Príncipe, Senegal, Solomon Islands, Sri Lanka, Sudan, Timor-Leste, Tunisia, Ukraine, Uzbekistan, Vanuatu, Vietnam, West Bank and Gaza, Zambia and Zimbabwe
- **Additional IDA eligible:** Dominica, Fiji, Grenada, Guyana, Kosovo, Maldives, Marshall Islands, Samoa, St. Lucia, St. Vincent and the Grenadines, Tonga and Tuvalu.



RESOURCES

- [who-covid19-vaccine-allocation-final-working-version-9sept](#)
- <https://www.gavi.org/covax-facility>
- <https://www.who.int/initiatives/act-accelerator/covax>
- <https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility>
- https://global-response.europa.eu/index_en
- <https://www.afro.who.int/news/african-countries-engaging-ground-breaking-covid-19-vaccine-initiative>

